



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Peter S. Linsley et al. **Examiner:** E. M. Lazar-Wesley, Ph.D.
Serial No.: 09/609,915 **Group Art Unit:** 1646
Filed: July 3, 2000 **Docket No.:** 30436.30USI2
Title: SOLUBLE CTLA4 MUTANT MOLECULES AND USES THEREOF

CERTIFICATE UNDER 37 CFR §1.8:

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Arlington, Virginia 22313-1450 on November 18, 2003.


By: Tracy Truick

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

(37 C.F.R. § 1.97(b)(3))

RECEIVED

NOV 28 2003

TECH CENTER 1600/2900

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

This statement should be considered because it is submitted before the mailing date of the first Office Action on the merits according to 37 C.F.R. §1.97(b)(3). In accordance with 37 C.F.R. §1.98(d), copy of Exhibit 260-261 as set forth in the Form 1449 are included herein.

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner. They are as follows:

- Brummell, David A. et al., "Probing the Combining Site of an Anti-Carbohydrate Antibody by Saturation-Mutagenesis: Role of the Heavy-Chain CDR3 Residues" *Biochemistry*, 1993, 32:1180-1187. – **Exhibit 260**
- Weissenhorn, Winifred et al., "VH-Related Idiotopes Detected By Site-Directed Mutagenesis, A Study Induced by the Failure to find CD4 Anti-Idiotypic antibodies Mimicking the cellular receptor of HIV1," *Journal of Immunology*, 1992, 149: 1237-1241 – **Exhibit 261**


Peter S. Linsley, et al.
Serial No. 09/609,915
Filed: July 3, 2000
Page 2

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that the references have been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. § 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

No fee is deemed necessary in connection with the filing of this Information Disclosure Statement on the merits of 37 C.F.R. §1.97(b)(3). However, if any additional fee is required, authorization is hereby given to charge the amount of any such fee, or credit any overpayment, to Deposit Account No. 50-0306.

Respectfully submitted,



Sarah B. Adriano
Registration No. 34,470
SaraLynn Mandel
Registration No. 31,853
Attorneys for Applicants
Mandel & Adriano
55 S. Lake Avenue, Suite 710
Pasadena, California 91101
(626) 395-7801
Customer No. 26,941

INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION

1646

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS							
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

[illegible]

RECEIVED

NOV 28 2003

TECH CENTER 1600/2900

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

*Substitute Disclosure Statement Form (PTO-1449)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE